The United Kingdom and the United States have secured a landmark bilateral deal that will guarantee zero import taxes on British drug exports entering the US market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has committed to increase spending on medicines through the public health system. This pledge guarantees that duties on these key products will stay at zero for a timeframe of three years.
This agreement is in response to previous threats to significantly raise import taxes on patented pharmaceutical products, with potential rates floated reaching 100%.
"This arrangement between the UK reinforces the worldwide climate for innovative medicines and introduces much-needed balance to U.S.–U.K. drug exports," a statement declared.
Commercial Importance
Drugs represent one of the the United Kingdom's biggest export categories to the United States, which is clearly the largest market for major British pharmaceutical firms.
Trade data reveal that in the one-year period leading up to last September, the UK shipped pharmaceutical products totaling over eleven billion pounds to the US. This amount represented nearly one-fifth of total UK exports in that timeframe.
"This agreement safeguards jobs, boosts investment and facilitates the UK to establish itself as a global hub for biotech and pharma," a minister commented.
Detailed UK Commitments
The deal entails several key changes from the British government:
- Price Threshold Increase: The UK will increase the affordability limit at which it judges new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to double overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The percentage manufacturers must pay back to the NHS to control costs will be restricted at fifteen percent. In the past, rebates exceeded 20%.
Broader Context
The pact follows a ongoing row between the sector and the British authorities over spending levels and regulatory access.
These tensions were intensified by arguments that US patients were charged several times more for the identical medicines than people in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or cancelled, while major expansions have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS needed to spend more on treatments, noting that its spending on drugs had declined as a percentage of its resources over the past decade.
